170 related articles for article (PubMed ID: 21558091)
1. Polo-like kinases and DNA damage checkpoint: beyond the traditional mitotic functions.
Bahassi el M
Exp Biol Med (Maywood); 2011 Jun; 236(6):648-57. PubMed ID: 21558091
[TBL] [Abstract][Full Text] [Related]
2. Getting in and out of mitosis with Polo-like kinase-1.
van Vugt MA; Medema RH
Oncogene; 2005 Apr; 24(17):2844-59. PubMed ID: 15838519
[TBL] [Abstract][Full Text] [Related]
3. Polo-like kinases and oncogenesis.
Eckerdt F; Yuan J; Strebhardt K
Oncogene; 2005 Jan; 24(2):267-76. PubMed ID: 15640842
[TBL] [Abstract][Full Text] [Related]
4. Polo-like kinase 1 reaches beyond mitosis--cytokinesis, DNA damage response, and development.
Takaki T; Trenz K; Costanzo V; Petronczki M
Curr Opin Cell Biol; 2008 Dec; 20(6):650-60. PubMed ID: 19000759
[TBL] [Abstract][Full Text] [Related]
5. Promotion of mitosis by activated protein kinase B after DNA damage involves polo-like kinase 1 and checkpoint protein CHFR.
Shtivelman E
Mol Cancer Res; 2003 Nov; 1(13):959-69. PubMed ID: 14638868
[TBL] [Abstract][Full Text] [Related]
6. Polo-like kinase-1 in DNA damage response.
Hyun SY; Hwang HI; Jang YJ
BMB Rep; 2014 May; 47(5):249-55. PubMed ID: 24667170
[TBL] [Abstract][Full Text] [Related]
7. Regulation of cell cycle checkpoints by polo-like kinases.
Xie S; Xie B; Lee MY; Dai W
Oncogene; 2005 Jan; 24(2):277-86. PubMed ID: 15640843
[TBL] [Abstract][Full Text] [Related]
8. Integrated computational model of cell cycle and checkpoint reveals different essential roles of Aurora-A and Plk1 in mitotic entry.
Zou J; Luo SD; Wei YQ; Yang SY
Mol Biosyst; 2011 Jan; 7(1):169-79. PubMed ID: 20978655
[TBL] [Abstract][Full Text] [Related]
9. Polo-like kinases and Chk2 at the interface of DNA damage checkpoint pathways and mitotic regulation.
Tsvetkov L
IUBMB Life; 2004 Aug; 56(8):449-56. PubMed ID: 15545224
[TBL] [Abstract][Full Text] [Related]
10. Aberrant Polo-like kinase 1-Cdc25A pathway in metastatic hepatocellular carcinoma.
Wang XQ; Zhu YQ; Lui KS; Cai Q; Lu P; Poon RT
Clin Cancer Res; 2008 Nov; 14(21):6813-20. PubMed ID: 18980975
[TBL] [Abstract][Full Text] [Related]
11. Yeast polo-like kinases: functionally conserved multitask mitotic regulators.
Lee KS; Park JE; Asano S; Park CJ
Oncogene; 2005 Jan; 24(2):217-29. PubMed ID: 15640837
[TBL] [Abstract][Full Text] [Related]
12. Schistosoma mansoni Polo-like kinase 1: A mitotic kinase with key functions in parasite reproduction.
Long T; Cailliau K; Beckmann S; Browaeys E; Trolet J; Grevelding CG; Dissous C
Int J Parasitol; 2010 Aug; 40(9):1075-86. PubMed ID: 20350550
[TBL] [Abstract][Full Text] [Related]
13. Polo-like kinases in AML.
Berg T; Bug G; Ottmann OG; Strebhardt K
Expert Opin Investig Drugs; 2012 Aug; 21(8):1069-74. PubMed ID: 22667760
[TBL] [Abstract][Full Text] [Related]
14. Plk1 depletion in nontransformed diploid cells activates the DNA-damage checkpoint.
Lei M; Erikson RL
Oncogene; 2008 Jun; 27(28):3935-43. PubMed ID: 18297112
[TBL] [Abstract][Full Text] [Related]
15. Polo-like kinase-1 is a target of the DNA damage checkpoint.
Smits VA; Klompmaker R; Arnaud L; Rijksen G; Nigg EA; Medema RH
Nat Cell Biol; 2000 Sep; 2(9):672-6. PubMed ID: 10980711
[TBL] [Abstract][Full Text] [Related]
16. Polo-like kinases and the microtubule organization center: targets for cancer therapies.
Dai W; Cogswell JP
Prog Cell Cycle Res; 2003; 5():327-34. PubMed ID: 14593727
[TBL] [Abstract][Full Text] [Related]
17. Non-mitotic functions of polo-like kinases in cancer cells.
Raab CA; Raab M; Becker S; Strebhardt K
Biochim Biophys Acta Rev Cancer; 2021 Jan; 1875(1):188467. PubMed ID: 33171265
[TBL] [Abstract][Full Text] [Related]
18. Polo-like kinase inhibitors: an emerging opportunity for cancer therapeutics.
Chopra P; Sethi G; Dastidar SG; Ray A
Expert Opin Investig Drugs; 2010 Jan; 19(1):27-43. PubMed ID: 20001553
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of Polo-like Kinase 1 inhibition on the G2/M checkpoint in Acute Myelocytic Leukaemia.
Didier C; Cavelier C; Quaranta M; Demur C; Ducommun B
Eur J Pharmacol; 2008 Sep; 591(1-3):102-5. PubMed ID: 18616938
[TBL] [Abstract][Full Text] [Related]
20. Polo-like kinase (PLK) inhibitors in preclinical and early clinical development in oncology.
Schöffski P
Oncologist; 2009 Jun; 14(6):559-70. PubMed ID: 19474163
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
